A pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. The landmark trial, presented at the 61st ERA Congress, will pave the way for new treatment strategies and offer hope to millions of patients globally. The study is also published in the New England Journal of Medicine. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study is a double-blind, randomized, placebo-controlled international trial comprising 3,533 patients, with a Read More
No comments:
Post a Comment